Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$0.91 - $1.7 $21,840 - $40,800
-24,000 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$2.0 - $3.65 $16,000 - $29,200
8,000 Added 50.0%
24,000 $56,000
Q2 2021

Aug 16, 2021

BUY
$5.3 - $7.4 $31,270 - $43,660
5,900 Added 58.42%
16,000 $118,000
Q1 2021

May 17, 2021

BUY
$5.54 - $8.1 $55,954 - $81,810
10,100 New
10,100 $60,000

Others Institutions Holding ARDS

About Aridis Pharmaceuticals, Inc.


  • Ticker ARDS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,701,600
  • Description
  • Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the...
More about ARDS
Track This Portfolio

Track Perritt Capital Management Inc Portfolio

Follow Perritt Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Perritt Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Perritt Capital Management Inc with notifications on news.